| Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program. | |
| | |
MedLine Citation:
|
PMID: 19296761 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Aliskiren is the first in a new class of orally effective direct renin inhibitors. Initial results of clinical efficacy studies have demonstrated at least equivalent or superior blood pressure-lowering efficacy when compared with existing drugs, and a favorable side-effect profile either as monotherapy or as a component of combination therapy. This report aims to introduce and provide a critical appraisal of the initial results of the ASPIRE HIGHER program, evaluating the potential cardio-renal protective effects of aliskiren. |
| | |
Authors:
|
Hae-Young Lee; Byung-Hee Oh |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of cardiovascular therapy Volume: 7 ISSN: 1744-8344 ISO Abbreviation: Expert Rev Cardiovasc Ther Publication Date: 2009 Mar |
Date Detail:
|
Created Date: 2009-03-19 Completed Date: 2009-06-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101182328 Medline TA: Expert Rev Cardiovasc Ther Country: England |
Other Details:
|
Languages: eng Pagination: 251-7 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul, Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Amides / administration & dosage, adverse effects, pharmacology* Antihypertensive Agents / administration & dosage, adverse effects, pharmacology* Blood Pressure / drug effects Clinical Trials as Topic Drug Therapy, Combination Fumarates / administration & dosage, adverse effects, pharmacology* Humans Hypertension / drug therapy* Renin / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Amides; 0/Antihypertensive Agents; 0/Fumarates; 0/aliskiren; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
Next Document: Multidisciplinary approach for circulatory support in patients with advanced heart failure.